Recipharm AB publishes its interim report January - September 2018
July – September 2018 · Net sales amounted to SEK 1,421 million (1,200), an increase of 18% · EBITDA increased by 47% and amounted to SEK 151 million (103) corresponding to an EBITDA margin of 10.6% (8.6) · Operating profit (EBIT) amounted to SEK 25 million (-17) · Profit after tax amounted to SEK -9 million (-54) corresponding to a net margin of -0.6% (-4.5) · Earnings per share amounted to SEK -0.13 (-0.89) before dilution and SEK -0.13 (-0.89) after dilution January – September 2018 · Net sales amounted to SEK 4,635 million (3,929), an increase of 18% ·